VVY (VVY) Stock News

Vivoryon Therapeutics (Euronext: VVY) completed a private placement on October 6, 2025, raising EUR 5.1 million by issuing 3,380,500 new ordinary shares at EUR 1.50 per share.

The placement equals 12.9% dilution of existing share capital, raises shares outstanding to 29,614,337, and increases share capital from EUR 262,338.37 to EUR 296,143.37.

Proceeds will fund near-term development of lead candidate varoglutamstat in diabetic kidney disease, support partnership negotiations, and provide a cash runway well into Q3 2026. New shares are expected to trade on Euronext Amsterdam on October 7, 2025 with delivery around October 9, 2025.

Vivoryon Therapeutics N.V. (VVY) reported H1 2025 financial results and significant progress in their kidney disease program. Key highlights include compelling kidney function data from two Phase 2 studies (VIVIAD and VIVA-MIND), showing varoglutamstat's ability to improve eGFR values. The company secured a new U.S. patent for varoglutamstat extending protection through 2044.

Financial results show a reduced net loss of EUR 5.5M compared to EUR 13.6M in H1 2024, with R&D expenses decreasing to EUR 2.8M from EUR 10.3M. Cash position stands at EUR 4.8M, expected to fund operations into January 2026. The company entered a EUR 15M Standby Equity Purchase Agreement with Yorkville Advisors and is actively seeking additional funding for planned Phase 2b DKD studies.

Pre-clinical data revealed synergistic effects when combining varoglutamstat with SGLT-2 inhibitors, showing promising results in inflammation, fibrosis, and kidney function markers.

Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), a clinical stage company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases, has scheduled its H1 2025 financial results announcement for September 4, 2025.

The company will host a conference call and webcast at 3:00 pm CEST / 9:00 am EDT. The financial report will be accessible on Vivoryon's website, and participants can join via phone by pre-registering through the provided link or attend via live audio webcast.

Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), a clinical stage company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases, has announced its upcoming participation in two virtual investor conferences.

Management will present at the mwb online Health Care Conference on July 1, 2025, at 12:00 pm CEST, and the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025, at 3:00 pm CEST / 9:00 am EDT. CEO Frank Weber and COO Julia Neugebauer will represent the company at both events.

Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), a clinical stage company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly diabetic kidney disease, held its 2025 Annual General Meeting (AGM) on June 24, 2025.

Shareholders approved all agenda items, including the appointment of Dr. Julia Neugebauer (COO since May 2025) as executive director. The meeting also confirmed the re-appointment of executive directors Dr. Frank Weber and Anne Doering, along with non-executive directors Dr. Erich Platzer, Charlotte Lohmann, Dr. Claudia Riedl, and Dr. Samir Shah.

Vivoryon Therapeutics reported Q1 2025 financial results and operational progress, focusing on advancing varoglutamstat for kidney disease treatment. Key highlights include encouraging preclinical data showing synergistic effects when combining varoglutamstat with SGLT-2 inhibitors, and a new U.S. patent extending exclusivity through 2044. The company's net loss decreased to EUR 2.5M from EUR 9.3M year-over-year, with cash position at EUR 7.0M as of March 31, 2025. R&D expenses decreased to EUR 1.2M from EUR 7.4M due to clinical trial completions. Vivoryon secured a EUR 15M Standby Equity Purchase Agreement with Yorkville Advisors and expects current funding to last until January 2026. The company plans to initiate a Phase 2b study in diabetic kidney disease, subject to additional funding or partnership.

Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) has announced it will release its Q1 2025 financial results and provide a corporate update on June 17, 2025. The company, which focuses on developing small molecule medicines for inflammatory and fibrotic disorders with an emphasis on kidney diseases, will host a public conference call and webcast at 3:00 pm CEST / 9:00 am EDT. Participants can access the live audio webcast through Vivoryon's website and join the conference call via phone by pre-registering through the provided link. Attendees are advised to join 15 minutes before the scheduled start time.

Vivoryon Therapeutics presented meta-analysis data for varoglutamstat, their lead drug candidate, at the 62nd ERA Congress in Vienna. The analysis combined results from two Phase 2 studies (VIVIAD and VIVA-MIND) conducted in the EU and US. The data showed statistically significant improvements in kidney function (eGFR) starting at week 24 and sustained through week 96. Notably, patients with diabetes demonstrated substantially larger benefits compared to non-diabetic participants. Varoglutamstat, a first-in-class glutaminyl cyclase inhibitor, showed both anti-inflammatory and anti-fibrotic effects. The company plans to advance the drug to a Phase 2b trial specifically focused on diabetic kidney disease patients with chronic kidney disease stage 3b/4, aiming to further investigate its effects on eGFR, proteinuria, and other kidney-specific markers.

Vivoryon Therapeutics N.V. (VVY) has strengthened its intellectual property portfolio with a new U.S. composition of matter patent for its lead drug varoglutamstat. The patent (US 12,312,335), granted after an accelerated examination, covers the active polymorph of varoglutamstat's salt form and provides exclusivity through 2044, with potential extension to 2049 under the Hatch-Waxman Act.

The company has also filed additional patents for medical use and dosing regimens in kidney disease, both as monotherapy and in combination with SGLT-2 inhibitors. Vivoryon's patent portfolio includes over 20 patent families and 400+ patent applications and issued patents covering major markets, with a focus on QPCT/L inhibitors for kidney diseases, inflammatory diseases, oncology, and fibrotic diseases.